Ned Berkowitz News Today

Voters in the Tamalpais Union High School District will decide whether to approve a $517 million bond measure to repair and replace aging facilities in the district's high schools.

/PRNewswire/ -- As the US braces for the upcoming fall and winter virus season, new survey data released today by the National Foundation for Infectious...

As an added benefit for Cherokee Media Group Premium Members, we are offering special episodes of the Auto Remarketing Podcast featuring general sessions from Used Car Week in November. Our next special episode features the "Auction Technology Part II: Auctions Executives on Tech’s Online and In-Lane Roles" panel discussion, which included Jaime Kruss of IAA, Kelly McAllister of America's Auto Auction, Ed Berkowitz of Cox Automotive, Jay Bahel of ADESA, Chris Angelicchio of Serv...

/PRNewswire/ -- With a potentially severe respiratory season ahead, about half of all US adults remain vulnerable to influenza (flu), according to new data...

/PRNewswire/ -- New survey data from the National Foundation for Infectious Diseases (NFID) show that while nearly 100 percent of healthcare professionals...

/PRNewswire/ -- New data released today by the National Foundation for Infectious Diseases (NFID) showed that 44 percent of US adults are unsure or do not plan...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Share this article Share this article BETHESDA, Md., Feb. 4, 2021 /PRNewswire/ -- New data released today by the National Foundation for Infectious Diseases (NFID) shows a significant gap in vaccine confidence among Black adults in the US. Despite bearing a disproportionate burden of serious disease and death related to COVID-19 and influenza (flu), a large percentage of Black adults say they will not get a COVID-19 vaccine when eligible, and they are either unsure or will not get a flu vaccine...

Almirall announces FDA approval of Klisyri® (tirbanibulin), a new innovative topical treatment for actinic keratosis -- Klisyri® (tirbanibulin) is a novel microtubule inhibitor, indicated for the topical treatment of actinic keratosis (AK) on the face or scalp -- Actinic keratosis is the second most common diagnosis made by dermatologists in the United States1 -- In one of the largest Phase III clinical study programs2 ever conducted for a topical AK treatment, tirbanibulin demonstrated compl...